CHAIR
:
SPEAKER
(S):
Alan Crane, CEO, Tempo Pharmaceuticals
Peter Wirth, Esq, Executive Vice President, Chief Legal Officer, Genzyme Corporation
Adelene Perkins, Executive Vice President, Chief Business Officer, Infinity Pharmaceuticals, Inc.
Clifford Stocks, Vice President, Business Development, Icos Corp.
Victor Hartmann, MD, Executive Vice President, Vertex Pharmaceuticals, Inc.
Description
How can a small company strike the right balance between the need for large amounts of cash to fuel investment and the desire to retain a significant stake in the value that is created? The panel will discuss various techniques for leveraging business development activity, platform technologies, commercial assets and other mechanisms to fuel growth without significant dilution.
Objectives:
Explore the constant tension between bringing in cash to fund the company and giving away ownership (of the company through dilution or of products through out-licensing).
Provide concrete, real-life experiences (both shareable best practices and unique successes) from executives who have creatively managed this process to maximize value for insiders and shareholders while building a company.